Nano-PSO delayed disease progression despite not reducing PrP accumulation, challenging the central dogma that prion protein reduction is necessary for therapeutic benefit. This raises fundamental questions about alternative therapeutic targets in prion diseases. Gap type: contradiction Source paper: Comparing anti-aging hallmark activities of Metformin and Nano-PSO in a mouse model of genetic Creutzfeldt-Jakob Disease. (2022, Neurobiology of aging, PMID:34875507)
Landscape Summary: Can therapeutic efficacy in genetic CJD be achieved without reducing pathological PrP accumulation? is a 0.76 priority gap in neurodegeneration. It has 0 linked hypotheses with average composite score 0.000. Status: open.
Colonna, Sevlever, et al. (TREM2 biology)
Can therapeutic efficacy in genetic CJD be achieved without reducing pathological PrP accumulation? — INVOKE-2 (completed)
No hypotheses linked to this gap yet.
No activity recorded yet.
No discussions yet. Be the first to comment.
Create sub-tasks to investigate specific aspects of this gap: